Home › NDC Lookup › RxCUI directory › RxCUI 313422

Tolnaftate 0.01 MG/MG Topical Powder — RxCUI 313422

RxNorm drug concept · Semantic clinical drug
RxCUI 313422 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI313422
Official nameTolnaftate 0.01 MG/MG Topical Powder
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astolnaftate 1 % Topical Powder
FDA products mapped5
Package NDCs mapped6
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tolnaftate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It depends on what you're treating. For athlete's foot and ringworm, plan on using it daily for about 4 weeks. For jock itch, 2 weeks is the usual course. Some products mention you...
  • How long does it take for tolnaftate to work?
  • Tolnaftate is not effective for treating infections on the scalp or on the nails themselves — most products say so right on the label. Some liquid and patch products are designed t...
  • Stop applying the product and let your doctor know. A little initial sensitivity can happen, but worsening irritation is a sign that you should get it checked out. Don't push throu...
📖 Read our full Tolnaftate guide →

🕸️ Concept Web — How Tolnaftate 0.01 MG/MG Topical Powder Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tolnaftate 0.01 MG/MG Topical Powder RxCUI 313422

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tolnaftate 10637
  2. Brand names 3

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Hongo Killer Antifungal 1101779
    • Lamisil Defense 692846
    • Tinactin 220322
  3. Dose forms 10

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tolnaftate Topical Powder 374462
    • Tolnaftate Topical Product 1157650
    • Tolnaftate Topical Powder [Hongo Killer Antifungal] 1101784
    • Tolnaftate Topical Powder [Lamisil Defense] 692848
    • Tolnaftate Topical Powder [Tinactin] 367505
    • Hongo Killer Antifungal Topical Product 1171277
    • Lamisil Defense Topical Product 1174988
    • Tinactin Topical Product 1179077
    • +2 more in this family
  4. Clinical & branded drugs 7

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Tolnaftate 0.01 MG/MG 340019
    • Tolnaftate 0.01 MG/MG Topical Powder [Hongo Killer Antifungal] 1101785
    • Tolnaftate 0.01 MG/MG Topical Powder [Lamisil Defense] 692849
    • Tolnaftate 0.01 MG/MG Topical Powder [Tinactin] 209660
    • Tolnaftate 0.01 MG/MG [Hongo Killer Antifungal] 1101783
    • Tolnaftate 0.01 MG/MG [Lamisil Defense] 692847
    • Tolnaftate 0.01 MG/MG [Tinactin] 570248

Showing up to 8 concepts per family — 19 of 21 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tolnaftate 0.01 MG/MG SCDC · 340019
  • Tolnaftate Topical Powder SCDF · 374462
  • Tolnaftate Topical Product SCDG · 1157650

Brand-Name Concepts

  • Tolnaftate 0.01 MG/MG Topical Powder [Hongo Killer Antifungal] SBD · 1101785
  • Tolnaftate 0.01 MG/MG Topical Powder [Lamisil Defense] SBD · 692849
  • Tolnaftate 0.01 MG/MG Topical Powder [Tinactin] SBD · 209660
  • Tolnaftate 0.01 MG/MG [Hongo Killer Antifungal] SBDC · 1101783
  • Tolnaftate 0.01 MG/MG [Lamisil Defense] SBDC · 692847
  • Tolnaftate 0.01 MG/MG [Tinactin] SBDC · 570248
  • Tolnaftate Topical Powder [Hongo Killer Antifungal] SBDF · 1101784
  • Tolnaftate Topical Powder [Lamisil Defense] SBDF · 692848
  • Tolnaftate Topical Powder [Tinactin] SBDF · 367505
  • Hongo Killer Antifungal Topical Product SBDG · 1171277

📦 FDA Products & Package NDCs

5 products · 6 package NDCs
6 package NDCs map to RxCUI 313422 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
11523-0011-01 90 g in 1 BOTTLE (11523-0011-1) Lotrimin Daily Prevention Bayer HealthCare LLC. 2020-02-14
11523-0011-02 28 g in 1 BOTTLE (11523-0011-2) Lotrimin Daily Prevention Bayer HealthCare LLC. 2022-11-01
57896-0199-45 45 g in 1 BOTTLE, DISPENSING (57896-199-45) TOLNAFTATE ANTIFUNGAL Geri-Care Pharmaceuticals, Corp 2011-08-01
58593-0288-07 200 g in 1 BOTTLE (58593-288-07) Hongo Killer Efficient Laboratories Inc 2016-05-02
71335-2249-01 45 g in 1 BOTTLE, DISPENSING (71335-2249-1) TOLNAFTATE ANTIFUNGAL Bryant Ranch Prepack 2024-01-29
73469-0619-04 113 g in 1 BOTTLE (73469-0619-4) Tolnaftate Antifungal Powder SCHOLL'S WELLNESS COMPANY LLC 2025-11-26
Observed labelers: Bayer HealthCare LLC. (2) · Bryant Ranch Prepack (1) · Efficient Laboratories Inc (1) · Geri-Care Pharmaceuticals, Corp (1) · SCHOLL'S WELLNESS COMPANY LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.